



A Specialty Pharmaceutical Company

NASDAQ: ANIP

HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING

Corporate Presentation

September 2013

Cautionary Statement Concerning Forward-Looking Statements

This presentation and certain information incorporated herein by reference contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that Company estimates regarding product development may not be realized; the Company may in the future fail to meet NASDAQ listing requirements; general business and economic conditions; the Company's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of the Company's licensees or sublicensees. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this quarterly report speak only as of the date made and are based on the Company's current beliefs and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Mission Statement

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

ANI’s mission is to utilize its manufacturing assets to develop and market niche generic pharmaceuticals, focusing on opportunities in pain management (narcotics), anti-cancer (oncolytics), women’s health (hormones and steroids), as well as complex formulations including extended release and combination products.

Company Overview – Poised for Growth

● ANI Today

- Core competencies: marketing and manufacturing
- Experienced management team
- Existing business + potential future royalty stream
 - For the interim six-month period ended June 30, 2013⁽¹⁾:
 - ❖ \$7.5 million Rx product revenues
 - ❖ \$4.2 million contract manufacturing and services revenues
 - ❖ Annual organic growth 17% year/year
 - Potential future royalty stream: Teva's Bio-T-Gel™
 - 12 products in development: total current market \$850 million⁽²⁾
- Two manufacturing facilities: narcotics and potent compounds
- Well-capitalized balance sheet: +\$12 million cash / no debt

Leadership – Deep Industry Experience

Senior Management

Arthur S. Przybyl, President and CEO
Charlotte C. Arnold, VP and CFO
Robert J. Jamnick, VP Quality and PD
James G. Marken, VP Operations
Robert W. Schrepfer, VP BD

ANI Since

2009
2009
2007
2007
2013

Previous Affiliation

Akorn (NASDAQ: AKRX)
MVP Capital Partners
Solvay
Solvay
Healthcare Value Capital

Board of Directors

Robert E. Brown, Jr. Chairman
Arthur S. Przybyl, President and CEO
Fred Holubow
Ross Mangano
Tracy Marshbanks
Thomas A. Penn
Daniel Raynor

Member Since

2009
2009
2013
2013
2006
2009
2013

History and Highlights


- 2004 Company founded with acquisition of over-the-counter pharmaceutical manufacturing plant in Gulfport, Mississippi
- 2007 ANI acquires two manufacturing plants located in Baudette, Minnesota from Solvay Pharmaceuticals
- 2009 New management team brought in by investors; Art Przybyl, CEO and Charlotte Arnold, CFO
- 2010 New strategy: ANI to focus on Rx products and contract manufacturing (Gulfport operation divested)
- 2011 ANI expands marketed Rx portfolio to seven products
- 2013 ANI completes reverse merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP)

Sales and Marketing Overview



Historical Revenue Growth

\$s in millions



● Cost of sales as a percentage of net revenues, excluding depreciation and amortization

(1) Unaudited

Current Rx Product Portfolio

<u>Generic Products</u>	<u>Position</u>	<u>Market Share⁽¹⁾</u>
Fluvoxamine Tablets	#1	54%
HC Enema	#1	85%
Opium Tincture	#1	64%
EE/MT Tablets	#2	42%
Metoclopramide Solution	#2	31%

Branded Products

Cortenema™

Reglan Tablets™

Contract Manufacturing and Royalties

● Current Business

- \$4.2 million in contract manufacturing and services revenues during the six-month period ended June 30, 2013⁽¹⁾
- Five customers
 - Eleven products and fourteen SKUs

● Future Opportunities

- Three customers in development
 - Three products and seven SKUs
- Potential future royalty: Teva's Bio-T-Gel™

Product Development / Business Development Overview



Product Development Highlights

- 12 products in development
 - Five filed ANDAs
 - Seven ANDAs in progress
 - Development partners: Ricon and Sofgen
 - Total combined current market: \$850 million⁽¹⁾

Therapeutic Category	Filed	In Development	Market Size ⁽¹⁾ (\$ in millions)
Oncolytics and Narcotics	3	2	\$97 million
Other (e.g. Extended Release, Combination Products)	2	5	\$753 million

(1) Based on Company estimates, and recent IMS and NSP Audit data

Business Development Highlights

- Acquired undisclosed ANDA, March 2010
- Acquired Reglan™ tablets, June 2011
- Product development partnership with Ricon, June 2011
- Acquired Bio-T-Gel™ royalty arrangement with Teva, June 2013
- Product development partnership with Sofgen, August 2013

Manufacturing Overview



Manufacturing – Main Street Facility

- Location: Baudette, Minnesota
 - 52,000 square feet of manufacturing, packaging, and warehouse facilities
 - Rx solutions, suspensions, topicals, tablets, and capsules
 - DEA-licensed for Schedule II controlled substances
 - 17,000 square feet of laboratory space for product development and analytical testing



Manufacturing – IDC Road Facility

- Location: Baudette, Minnesota
 - Fully-contained high potency facility with capabilities to manufacture hormone, steroid, and oncolytic products
 - 47,000 square feet of manufacturing and packaging, and warehouse facilities
 - 100 nano-gram per eight-hour weighted average maximum exposure limit to ensure employee safety
 - DEA Schedule IIIN capability



Capitalization and Shareholders



Capitalization and Shareholders

- Market capitalization (as of September 18th, 2013) of approximately \$85 million
- 9.5 million shares outstanding
- Major shareholders

	Ownership
Officers and Directors	3.7%
Meridian Venture Partners	29.6%
First Analysis Corporation	8.5%
Argentum Capital Partners II	5.9%
Healthcare Value Capital LLC	3.9%

Poised for Growth